EFFECTS OF S-8527 (1, 1-BIS [4'-CARBOXY-1''-METHYLPROPOXY) PHENYL] CYCLOHEXANE), A NEW HYPOLIPIDEMIC COMPOUND, ON PLATELET AGGREGATION, ADHESIVENESS AND BLOOD COAGULATION IN RATS

Kotaro SUZUKI

Research Department, Pharmaceuticals Division, Takarazuka Research Laboratories, Sumitomo Chemical Co Ltd., Takarazuka, Japan

Accepted April 30, 1975

Abstract—Effects of S-8527 (1,1-bis[4'-carboxy-1''-methylpropoxy) phenyl] cyclohexane) on platelet aggregation, adhesiveness and blood coagulation were examined in rats. In animals maintained on a semisynthetic diet containing sucrose (62%) as the only carbohydrate source, platelet adhesiveness increased as compared with that in rats fed a normal chow pellet. Under these experimental conditions, oral dose of S-8527 (30-300 mg/kg) for 14 days decreased platelet adhesiveness and ADP-induced platelet aggregation, but did not decrease collagen-induced platelet aggregation. S-8527 also showed a slight but significant increase of R value of thrombelastograph. In rats which were fed a normal chow pellet oral dose of S-8527 for 14 days did not significantly affect the several tests of platelet function and blood coagulation. These results suggest that S-8527 normalizes the platelet function in a hyper-adhesive state, but does not affect the platelet function in a normal state.

Hyperlipidemia is considered a major risk factor in the development of atherosclerosis (1, 2). Pharmacological agents that decrease plasma lipid concentration are currently being used in an attempt to prevent atherosclerosis and its complications (3-6). We have shown that the hypolipidemic effect of S-8527 (1,1-bis [4'-carboxy-1''-methylpropoxy) phenyl] cyclohexane) is about ten times more potent that that of elofibrate but the hepatomegalic effect of S-8527 is far less that that of clofibrate in rats (7-10).

There is also an important relationship between intra-arterial thrombosis and atherosclerosis, not only because intra-arterial thrombosis is partly responsible for the mortality due to atherosclerosis (11), but also because it probably plays a primary role in etiology of the atherosclerosis process (12).

In the present study, the effects of S-8527 on so called “thrombogenic parameters” (platelet aggregation, platelet adhesiveness, thrombelastography values, clotting times and fibrinogen levels) were studied in rats.

MATERIALS AND METHODS

Treatment of animals

Male Wistar rats weighing 200-250 g were fed a semisynthetic diet containing sucrose as the only carbohydrate source or a normal chow pellet diet (NIPPON CLEA, CE-2). The composition of the semisynthetic diet used was as follows: 62% sucrose, 18% casein,
5% lard, 8% cellulose powder, 5% salt mixture (U.S.P. XVII) and 2% vitamin mixture.

S-8527 and clofibrate were suspended in an appropriate amount of 5% gum arabic solution, so that the daily dose would be 0.5 ml per 100 g of body weight: it was given to the rats via stomach tube every a.m. for 14 days. Control groups were on an equal volume of the vehicle. Twenty-four hours after the last dose of S-8527 or clofibrate, the rats were anesthetized with ether. Blood was collected from the inferior vena cava into a polyethylene test tube containing 1 vol. of 3.8% citrate per 9 vol. of blood. Citrated whole blood samples from two rats were pooled to study the effects on platelet aggregation, thrombelastography values, clotting tests and plasma components.

Assay of platelet aggregation

This study was performed according to the method of Mills and Roberts (13). Platelet rich and platelet poor plasma were prepared by centrifuging citrated blood at 1,500 rpm for 15 min and 3,000 rpm for 20 min, respectively, at room temperature. Plasma was transferred to the polyethylene tube at room temperature for immediate testing. An aggregometer (Bryston, Canada) was used. Samples of 0.5 ml of platelet rich plasma were pipetted into the cuvette and warmed to 37° stirring at 1,100 rpm before adding a stimulus. After 5 min, 0.05 ml of ADP or collagen in Tris-saline (13) was added to the cuvette (final ADP concentration in platelet rich plasma was 2.5 µg/ml or 10 µg/ml, and final collagen concentration was 100 µg/ml). Suspension of collagen was prepared using a glass homogenizer. The degree of aggregation was measured after addition of a stimulus by the maximum change in optical density of platelet rich plasma when the sensitivity was adjusted to 0 in optical density (100% transmittance) with platelet poor plasma.

Assay of thrombelastography value

This was carried out as described by Hartert (14). In a polyethylene tube, 0.6 ml of the citrated whole blood was pipetted with the aid of a polyethylene pipette and 0.4 ml of 0.25 M CaCl₂ solution was added. Immediately after mixing the blood samples, 0.36 ml of the mixture was put into the cell which had been placed in the thrombelastograph.

Determination of clotting times

Assay of recalcification time, partial thromboplastin time, prothrombin time and thrombin time was carried out using the citrated platelet poor plasma (15).

Assay of platelet adhesiveness

Platelet adhesiveness to glass beads was tested by the Salzman method (16). A piece of polyvinyl tube (2.8 x 120 mm) which filled with glass beads (0.6-0.7 mm, diameter) was used. Blood was collected from the inferior vena cava of the rats, which had been anesthetized with ether 24 hr after the last dosing, through the glass tube into polyethylene syringe containing a small amount of EDTA (2Na). The rate of blood flow through the column was standardized to 1 ml per 36 sec using a motor-driven syringe. The difference in the platelet count before and after the passage of the column represents the number of adhesive platelets and this is expressed as a percentage of pre-filter count. Platelet count was done on a Coulter Thrombocounter (17).
Assay of fibrinogen and plasma lipids

Fibrinogen levels were determined as total thrombin-precipitable protein by the method of Lowry et al. (18) after syneresis of the clots on filter paper. Plasma triglycerides and cholesterol were assayed using a Technicon Autoanalyzer (19).

Chemicals

S-8527 was synthesized in this laboratory. Clofibrate (ethyl p-chlorophenoxyisobutyrate) was obtained from Imperial Chemical Industries Ltd. in England.

RESULTS

In the first experiment, the rats were maintained on a semisynthetic diet containing sucrose (62%) as the only carbohydrate source. Table 1 shows the effects on the several tests of platelet function. After the feeding of a semisynthetic diet for 14 days, platelet adhesiveness increased almost double in comparison with that in the rats on a normal chow pellet diet. Platelet aggregation and platelet count showed no significant changes between the rats on a semisynthetic diet and those on a normal chow pellet. In rats given a daily oral dose of S-8527, platelet adhesiveness decreased by about 23% at a dose of 30 mg/kg and 30% at a dose of 300 mg/kg, respectively. ADP-induced platelet aggregation decreased by about 25-50% at a dose of 300 mg/kg, but collagen-induced platelet aggregation was not significantly altered by S-8527. On the other hand, clofibrate (300 mg/kg) decreased collagen-induced platelet aggregation by about 28%, but did not significantly alter ADP-induced platelet aggregation and platelet adhesiveness. No significant alteration in the platelet count between control and S-8527 or clofibrate treated groups was found. Table

| Treatment | Platelet aggregation | Platelet adhesiveness (%) | Platelet count (10⁶/mm³) |
|-----------|----------------------|---------------------------|--------------------------|
|           | ADP 10 µg/ml          |                          |                          |
|           | (mg/ml)               |                          |                          |
|           | maximum change of optical density | Salzman tube test |                          |
| Control   | 59.5 (7)              | 57.4 (6)                 | 61.7 (9)                 |
| S-8527    | 55.5 (7)              | 46.3 (6)                 | 47.1 (9)                 |
| 30 mg/kg  | 54.7 (7)              | 43.4 (6)                 | 44.2 (9)                 |
| S-8527    | 44.0* (7)             | 43.4 (6)                 | 51.9 (9)                 |
| 300 mg/kg | -5.7 (7)              | 41.3* (6)                | 51.9 (9)                 |
| Clofibrate| 59.4 (7)              | 42.9 (6)                 | 51.9 (9)                 |
| 300 mg/kg | 54.6 (6)              | 41.3 (6)                 | 51.9 (9)                 |
| Normal diet| 60.5 (6)              | 52.6 (6)                | 34.6** (9)               |
|           | 1.6 (6)               | 1.3 (6)                  | 3.2 (9)                  |

For studying the effects on platelet aggregation, blood samples from two rats were pooled. Each value represents the means ± S.E. for the number of determinations shown in parentheses. In the study of platelet adhesiveness and platelet count, each value represents the mean ± S.E. for the number of animals indicated in parentheses.

* Significantly different from control (P<0.05)

** Significantly different from control (P<0.01).
Table 2. Effects of S-8527 and clofibrate on thrombelastography values in rats fed a semisynthetic diet containing sucrose as the only carbohydrate source.

| Treatment          | R (min) | K (min) | R / K (min) | MA (mm) |
|--------------------|---------|---------|-------------|---------|
| Control            | 1.8 ± 0.1 | 1.9 ± 0.4 | 3.7 ± 0.5  | 59.2 ± 2.7 |
| S-8527 30 mg/kg    | 2.5 ± 0.2** | 2.2 ± 0.3 | 4.6 ± 0.2  | 56.0 ± 2.3 |
| S-8527 300 mg/kg   | 2.6 ± 0.1*** | 2.2 ± 0.3 | 4.9 ± 0.2* | 54.1 ± 2.1 |
| Clofibrate 300 mg/kg | 2.2 ± 0.1 | 2.5 ± 0.3 | 4.9 ± 0.2  | 55.0 ± 0.6 |
| Normal diet        | 2.0 ± 0.1 | 2.1 ± 0.3 | 4.1 ± 0.4  | 59.0 ± 1.3 |

Blood samples from two rats were pooled. Each value represents the mean ± S.E. for the number of determinations shown in parentheses.

R, reaction time. K, clot-formation time. MA, maximum amplitude.

* Significantly different from control (P < 0.05).
** Significantly different from control (P < 0.01).
*** Significantly different from control (P < 0.001).

Table 3. Effects of S-8527 and clofibrate on clotting tests, fibrinogen and plasma lipid levels in rats fed a semisynthetic diet containing sucrose as the only carbohydrate source.

| Treatment            | Control | S-8527 30 mg/kg | S-8527 300 mg/kg | Clofibrate 300 mg/kg | Normal diet |
|----------------------|---------|-----------------|------------------|----------------------|------------|
| Recalcification time (sec) | 58.5 ± 2.5 | 63.0 ± 4.8 | 68.6 ± 6.2 | 61.4 ± 4.2 | 64.5 ± 2.8 |
| Partial thromboplastin time (sec) | 30.5 ± 1.1 | 32.0 ± 1.6 | 30.1 ± 1.0 | 29.9 ± 0.6 | 29.7 ± 1.8 |
| Prothrombin time (sec) | 14.8 ± 0.3 | 16.3 ± 0.5* | 15.9 ± 0.7 | 15.1 ± 0.4 | 14.4 ± 0.2 |
| Thrombin time (sec)   | 13.7 ± 0.6 | 15.4 ± 0.9 | 14.2 ± 0.5 | 12.8 ± 1.2 | 14.4 ± 0.5 |
| Fibrinogen (mg/100 ml) | 223.2 ± 24.2 | 216.4 ± 26.4 | 205.3 ± 48.2 | 158.3 ± 22.3 | 205.0 ± 11.9 |
| Plasma triglycerides (mg/100 ml) | 103.7 ± 8.5 | 46.9 ± 4.3*** | 35.9 ± 4.3*** | 60.1 ± 8.5** | 131.2 ± 5.3 |
| Plasma cholesterol (mg/100 ml) | 76.1 ± 3.1 | 47.5 ± 4.8*** | 36.5 ± 4.8*** | 49.8 ± 1.3*** | 56.2 ± 2.1*** |

Blood samples from two rats were pooled. Each value represents the mean ± S.E. for the number of determinations shown in parentheses.

* Significantly different from control (P < 0.05).
** Significantly different from control (P < 0.01).
*** Significantly different from control (P < 0.001).
### TABLE 4. Effects of S-8527 and clofibrate on several tests of platelet function in rats fed a normal chow diet

| Treatment       | Platelet aggregation (ADP 10 µg/ml) | Platelet adhesiveness (Salmaz tube test) | Platelet count (x10^9/mm³) |
|-----------------|-------------------------------------|----------------------------------------|---------------------------|
|                 | maximum change of optical density (ΔO.D. x10⁶) | % | |
| Control         | 51.8 ± 8.2 (7)                      | 49.4 ± 7.4 (9)                        | 39.7 ± 1.4 (9)            |
| S-8527 30 mg/kg | 55.2 ± 9.2 (7)                      | 46.8 ± 8.0 (10)                       | 40.6 ± 2.5 (10)           |
| S-8527 300 mg/kg| 52.9 ± 2.7 (9)                      | 49.6 ± 6.5 (9)                        | 52.9 ± 8.7 (7)**          |
| Clofibrate 300 mg/kg | 49.2 ± 10.4 (7)                | 54.7 ± 8.5 (9)                        | 42.2 ± 3.6 (9)            |

For studying the effects on platelet aggregation, blood samples from two rats were pooled. Each value represents the mean ± S.E. for the number of determinations shown in parentheses. In the study platelet adhesiveness and platelet count, each value represents the mean ± S.E. for the number of animals shown in parentheses. ** Significantly different from control (P<0.01).

### TABLE 5. Effects of S-8527 and clofibrate on thrombelastography values in rats fed a normal chow diet

| Treatment       | Thrombelastography values |
|-----------------|---------------------------|
|                 | R (min) | K (min) | R – K (min) | MA (mm) |
| Control         | (7)     | 1.9±0.2 | 2.1±0.3     | 4.0±0.4 | 55.3±2.1 |
| S-8527 30 mg/kg | (7)     | 2.2±0.2 | 1.8±0.3     | 4.1±0.3 | 58.3±2.2 |
| S-8527 300 mg/kg| (7)     | 2.3±0.2 | 2.4±0.5     | 4.6±0.5 | 55.9±2.2 |
| Clofibrate 300 mg/kg | (7)     | 2.2±0.2 | 2.9±0.2**   | 5.1±0.3* | 51.3±3.3 |

Blood samples from two rats were each pooled. Each value represents the mean ± S.E. for the number of determinations shown in parentheses.  
R, reaction time. K, clot-formation time. MA, maximum amplitude.  
* Significantly different from control (P<0.05). ** Significantly different from control (P<0.01).

### TABLE 6. Effects of S-8527 and clofibrate on clotting tests, fibrinogen and plasma lipid levels in rats fed a normal chow diet

| Treatment                  | Control | S-8527 30 mg/kg | S-8527 300 mg/kg | Clofibrate 300 mg/kg |
|---------------------------|---------|----------------|-----------------|----------------------|
| Recalcification time (sec) | 60.1 ± 1.7 (7) | 60.6 ± 3.5 (7) | 65.7 ± 3.7 (7) | 59.1 ± 3.1 (7) |
| Partial thromboplastin time (sec) | 29.8 ± 0.8 (7) | 28.9 ± 1.2 (7) | 26.8 ± 0.9 (7) | 28.6 ± 0.8 (7) |
| Prothrombin time (sec)     | 14.5 ± 0.1 (4) | 15.3 ± 3.6 (4) | 14.8 ± 0.5 (4) | 14.6 ± 0.2 (4) |
| Thrombin time (sec)        | 12.8 ± 0.6 (7) | 12.2 ± 0.2 (7) | 12.3 ± 0.2 (7) | 11.6 ± 0.3 (7) |
| Fibrinogen (mg/100 ml)     | 196.7 ± 11.9 (7) | 195.4 ± 14.2 (6) | 159.5 ± 6.4* (7) | 164.5 ± 19.6 (7) |
| Plasma triglycerides (mg/100 ml) | 119.6 ± 7.3 (7) | 60.3 ± 7.0*** (7) | 41.8 ± 3.0*** (7) | 60.8 ± 5.6*** (7) |
| Plasma cholesterol (mg/100 ml) | 55.1 ± 2.1 (7) | 40.4 ± 3.5** (7) | 37.7 ± 2.7*** (7) | 44.2 ± 3.9* (7) |

Blood samples from two rats were pooled. Each value represents the mean ± S.E. for the number of determinations shown in parentheses.  
* Significantly different from control (P<0.05).  
** Significantly different from control (P<0.01).  
*** Significantly different from control (P<0.001).
S-8527 lowered plasma lipids more effectively than clofibrate as previously reported (7, 8).

In the second experiment, the rats were maintained on a normal chow pellet diet. S-8527 and clofibrate did not show significant effects in the several tests of platelet function (Table 4), thrombelastography values (Table 5) and clotting tests (Table 6) but did decrease fibrinogen levels (Table 6).

**DISCUSSION**

In rats on a semisynthetic diet containing sucrose as the only carbohydrate source, platelet adhesiveness and plasma cholesterol increased as compared with those in rats on a normal chow diet. There were also tendencies to an increase of fibrinogen levels, and decreases of R value and recalcification time. These results indicate that the animals fed a semisynthetic diet containing sucrose as the only carbohydrate source are in a hyperadhesive, a hypercoagulable and a hyperlipidemic state. Dietary sucrose has been shown to have a influence on serum lipids in man (20, 21) and animals (22, 23). It was also reported that dietary sucrose increased platelet adhesiveness in man (24). These effects were confirmed in the present study. Under these experimental conditions, an oral dose of S-8527 for 14 days decreased the platelet adhesiveness and platelet aggregation, and increased the R value. But when S-8527 was given to rats fed a normal diet, these effects of S-8527 were absent, which suggests that S-8527 may not affect the platelet function and blood coagulability in a normal state but in a hyperadhesive and a hypercoagulable state. S-8527 may normalize the platelet function and blood coagulability.

S-8527 lowered plasma lipids in both the rats fed a semisynthetic diet and those fed a normal diet. However, S-8527 decreased the platelet function in the rats fed a semisynthetic diet containing sucrose as the only carbohydrate source. These results suggest that the effects of S-8527 in platelet function are independent of its effects on lipid levels.

It is generally acceptable that endogenous fatty acid synthesis is increased and the composition of the fatty acid is altered by feeding sucrose (20–24). The decrease in unsaturated fatty acid levels and accumulation of saturated fatty acid are observed. Nordøy (25) and Day et al. (26) reported that saturated fatty acids increased platelet adhesiveness and promoted thrombosis. A hyperadhesive and hypercoagulable state in rats fed a semisynthetic diet containing sucrose as the only carbohydrate source may be the results of altered tissue or plasma lipid properties. S-8527 was reported to decrease the endogenous triglyceride synthesis (9). Therefore, it is possible that accumulation of saturated fatty acid is decreased by S-8527, and a hyperadhesive and hypercoagulable state is returned to a normal one.

The action of clofibrate on lipid functions has been extensively confirmed by a number of clinical and experimental studies (27). Reduced platelet adhesiveness and platelet aggregation have been observed in several series in the course of treatment with clofibrate in man, although such findings have not always been confirmed (11). In the present studies, clofibrate decreased collagen-induced platelet aggregation but did not affect the other tests of platelet function and blood coagulation.
Aggregability and adhesiveness of platelets are increased in certain diseases including atherosclerosis (28). Other studies suggested that platelet suppressing drugs may exert favorable effects regarding mortality from vascular diseases (11, 29). S-8528 may be applicable for the treatment of patients with a hypercoagulable, hyperadhesive and hyperaggregable picture in platelet analysis.

Acknowledgements: The author wishes to thank Drs. S. Yamaoka, K. Toki, H. Nakatani and S. Aono for their pertinent advice and encouragement during this study.

REFERENCES

1) DAWBER, T.R., KANNEL, W.B., REVOTSKIE, N. AND KAGAN, A.: Proc. R. Soc. Med. 55, 265 (1962)
2) ALBRINK, M.J.: Arch. Intern. Med. 109, 345 (1962)
3) DEWAR, A.H.: Brit. Med. J. 4, 767 (1971)
4) OLIVER, M.F.: Brit. Med. J. 4, 775 (1971)
5) KRASNO, L.R. AND KIDERA, G.J.: J. Am. Med. Assoc. 219, 845 (1972)
6) KRITCHEVSKY, D.: Lipid 9, 97 (1974)
7) TOKI, K., NAKAMURA, Y., AGATSUMA, K., NAKATANI, H. AND AONO, S.: Atherosclerosis 18, 101 (1973)
8) SUZUKI, K., AONO, S. AND NAKATANI, H.: Jap. J. Pharmacol. 24, 407 (1974)
9) SUZUKI, K.: Biochem. Pharmacol. 24, 1203 (1975)
10) SUZUKI, K.: Biochem. Pharmacol. (in press)
11) HAMPTON, J.: Am. J. Cardiol. 27, 659 (1971)
12) DUGUID, J.B.: J. Path. Bact. 60, 57 (1948)
13) MILLS, D.C.B. AND ROBERTS, G.C.K.: J. Physiol. 193, 443 (1967)
14) HARTERT, H.: Klin. Wscher. 26, 577 (1948)
15) BELLER, F.K. AND GRAFF, H.: Thrombosis and Bleeding Disorders, Edited by BANG, N.U., BELLER, F.K. DEUTSCH, E. AND MAMMEN, E.F., p. 65, Academic Press, New York (1971)
16) SALZMAN, E.W.: J. Lab. clin. Med. 62, 724 (1963)
17) BELL, B.S. SCHNIEERMAN, M.A. AND BRECHER, G.: Am. J. Clin. Path. 44, 678 (1965)
18) LOWRY, O.H., ROSEBROUGH, N.J., FARR, A.L. AND RANDALL, R.J.: J. biol. Chem. 193, 265 (1951)
19) Technicon Laboratory Method, N-24A and N-78
20) Kuo, P.T. AND BASSETT, D.R.: Am. Intern. Med. 62, 1199 (1965)
21) KAUFMAN, N.A., POZNANSKI, R., BLONDHEIM, S.H. AND STEIN, Y.: Am. J. Clin. Nutr. 18, 261 (1966)
22) PORTMAN, O.W., LAWRY, E.Y. AND BRUNO, D.: Proc. Soc. exp. Biol. Med. 91, 321 (1956)
23) COHEN, A.M. AND TITTELBAUM, A.: Life Sci. 7, 23 (1968)
24) MATSUDA, T.: Japan. J. Clin. Path. 21, 886 (1972)
25) NORDÖY, A.: Thromb. Diath. Haemorrh. 13, 543 (1965)
26) DAY, H.J., FEWELL, W. AND SOLOFF, L.A.: Am. J. Med. Sci. 253, 83 (1967)
27) HAVEL, R.J. AND KANE, J.P.: Am. Rev. Pharmacol. 13, 287 (1973)
28) CARVALHO, A.G.A., COLMAN, R.W. AND LILES, R.S.: New. Engl. J. Med. 290, 434 (1974)
29) MUSTARD, J.F. AND PACKHAM, M.A.: Biochem. Pharmacol. 22, 3151 (1973)